The addition of bevacizumab to letrozole capitalizes on multiple lines of evidence that implicate VEGF and angiogenesis as major mediators of resistance to endocrine therapies in luminal breast cancer [2–6, 13–15]. The gene discussed is VEGFA; the disease is breast cancer.